Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Charles River Laboratories Intl (NY: CRL )

193.79 +0.08 (+0.04%)
Official Closing Price Updated: 7:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Charles River Laboratories Intl

< Previous 1 2 3 Next >
Bragar Eagel & Squire, P.C. Is Investigating Fox, FTX, RH, and Charles River and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Globe NewsWire
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Charles River Laboratories International, Inc. Investors to Inquire About Securities Class Action Investigation - CRL
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Law Enforcement Supply Chain
Exposures Legal Supply Chain
Charles River Laboratories International, Inc. (NYSE:CRL) Investor Alert: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 03/13/2023 -- An investigation was announced for investors of Charles River Laboratories International, Inc. (NYSE:CRL) shares over potential securities laws violations by... 
Via SBWire
Charles River Launches Apollo™, an Industry-Leading, Secure, Cloud-Based Platform for Real-Time Toxicology Study Data
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at Barclays Global Healthcare Conference
From Charles River Laboratories International, Inc.
Via Business Wire
ROSEN, NATIONAL TRIAL ATTORNEYS, Encourages Charles River Laboratories International, Inc. Investors to Inquire About Securities Class Action Investigation - CRL
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Law Enforcement Supply Chain
Exposures Legal Supply Chain
Charles River Launches Helper Plasmid to Streamline Adeno-Associated Viral Vector Manufacturing
From Charles River Laboratories International, Inc.
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Fox, Norfolk Southern, Charles River, and CCSI and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Globe NewsWire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Charles River Laboratories International, Inc. Investors to Inquire About Securities Class Action Investigation - CRL
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Law Enforcement Supply Chain
Exposures Legal Supply Chain
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Charles River Laboratories International, Inc. Investors to Inquire About Securities Class Action Investigation - CRL
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Law Enforcement Supply Chain
Exposures Legal Supply Chain
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Charles River Laboratories International, Inc. (CRL) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Charles River Laboratories International, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - CRL
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Law Enforcement Supply Chain
Exposures Legal Supply Chain
CHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Charles River Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Charles River Laboratories International, Inc. (CRL) Investors of Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
CRL EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Charles River Laboratories International, Inc. Investors With Losses In Excess of $100K to Inquire About Securities Class Action Investigation – CRL
From The Rosen Law Firm, P.A.
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Charles River Laboratories International, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Charles River Laboratories International, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Charles River Laboratories International, Inc. (CRL) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Charles River Laboratories International, Inc. (CRL) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Charles River Laboratories International, Inc. (CRL) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Launches Novel IgY-based ELISA Kit for the Detection and Quantitation of Residual Host Cell Protein
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules Fourth-Quarter 2022 Earnings and 2023 Guidance Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Acquires SAMDI Tech
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing Alliance
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Launches CliniPrime Suite of GMP-Compliant Cellular Products
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Establishes eXpDNA™ Plasmid Manufacturing Platform to Expedite DNA Programs
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
From Charles River Laboratories International, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.